Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent

Cancer

Volumn 112, Issue 1, 2008, Pages 69-74

  Kattan, Michael W ^a   Cuzick, Jack ^b   Fisher, Gabrielle ^b   Berney, Daniel M ^c   Oliver, Tim ^c   Foster, Christopher S ^d   Møller, Henrik ^e   Reuter, Victor ^f   Fearn, Paul ^f   Eastham, James ^f   Scardino, Peter T ^f  

^a LERNER RESEARCH INSTITUTE   (United States)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Curative intent; Nomogram; Prostate cancer; Watchful waiting

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; DIAGNOSTIC ACCURACY; DISEASE FREE SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; STATISTICAL MODEL; VALIDITY;

ADULT; AGED; BIOPSY; COHORT STUDIES; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; NOMOGRAMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 37448998966     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23106     Document Type: Article

References (11)

1. Albertsen P, Hanley J, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293:2095-2101.
2. Albertsen JL, Hanley JA, Gleason DF. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998;280:975.
3. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 2001;58:843-848.
4. Shipley WU, Thames HD, Sandler HM, et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA. 1999;281:1598-1604.
5. Tewari A, Johnson CC, Divine G, et al. Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities. J Urol. 2004;171:1513-1519.
6. Cuzick J, Fisher G, Kattan M, et al. Long-term outcome among men with conservatively treated localized prostate cancer. Br J Cancer. 2006;95:1186-1194.
7. Deshmukh N, Foster C. Grading Prostate Cancer. Philadelphia: WB Saunders; 1997.
8. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-387.
9. Harrell FE Jr. Regression Modeling Strategies With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer; 2001.
10. Eastham JA, Groshen SL, Kattan MW, et al. Fifteen-year survival and recurrence rates after radiotherapy for localized prostate cancer. J Clin Oncol. 1997;15:3214-3222.
11. Kattan MW. Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer. Curr Opin Urol. 2003;13:111-116.